Clinical trials
No Disease or Condition is Being Studied clinical trials
Below are recruiting no disease or condition is being studied clinical trials, each written for real people, not researchers. We’re tracking 18,404 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06555965Recruiting
STXBP1 and SYNGAP1 natural history study
This study follows people with STXBP1 or SYNGAP1 gene changes over time to learn more about how these conditions affect the body and mind. It does not test a treatment but helps researchers understand the natural course of the disorder.
Palo Alto, CaliforniaAges Any age - NCT06540833RecruitingPhase 2
Study of a new drug for psychosis in people with Alzheimer's disease
This trial tests an experimental medication to reduce hallucinations and delusions in people who have Alzheimer's disease. It may help manage these symptoms and improve quality of life for patients and their caregivers.
Anaheim, CaliforniaAges 55 years+ - NCT06546670RecruitingPhase 1/Phase 2
Study of ITU512 for sickle cell disease
This trial tests a new medicine called ITU512 in two groups: healthy volunteers and people with sickle cell disease. In the second part, researchers want to see if ITU512 can help manage sickle cell disease.
Birmingham, AlabamaAges 12–55 - NCT06548542RecruitingPhase 2
Targeted drug study for moderate to severe Crohn's disease
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
Dothan, AlabamaAges 18–75 - NCT06548607RecruitingEarly Phase 1
CAR-T therapy for autoimmune diseases
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
Bengbu, AnhuiAges 18–70 - NCT06519162Recruiting
Liver-gut link study for liver disease patients and their families
This study looks at how gut bacteria differ in people with specific liver diseases and their household contacts. It may help researchers understand the connection between the liver and gut.
Daejeon, Jung-guAges 19 years+ - NCT06514001RecruitingPhase 2
Testing a new drug for Alzheimer's disease with eye scans
This trial tests an investigational drug called AMDX-2011P for people with Alzheimer's disease. It looks at whether the drug affects the retina, which may be linked to brain changes in Alzheimer's.
Phoenix, ArizonaAges 18 years+ - NCT06506942Recruiting
TRICURE device study for leaky heart valve
This study tests a new device to help people with severe tricuspid regurgitation (leaky heart valve) who are at higher risk from surgery. It aims to see if the device can reduce the leak and improve symptoms.
Atlanta, GeorgiaAges 18 years+ - NCT06495554Recruiting
Danish vulva cancer recurrence study
This study looks at how vulva cancer returns (recurrence) over time. It aims to improve follow-up care for people who have had this type of cancer.
Aarhus NAges 18 years+ - NCT06475898Recruiting
Tracking Huntington's disease burden over time
This study follows people with Huntington's disease (or those who carry the gene) over time using online surveys. It aims to better understand how the disease progresses, which could help improve future care.
Rochester, New YorkAges 18 years+ - NCT06466135RecruitingPhase 2
Study of WAL0921 for glomerular kidney diseases
This study tests a new drug called WAL0921 for people with certain types of kidney disease. The goal is to see if it can help protect kidney function.
Los Angeles, CaliforniaAges 18–75 - NCT06466785RecruitingPhase 3
Study of Efepoetin Alfa for anemia in kidney dialysis patients
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
YerevanAges 18 years+ - NCT06467344RecruitingPhase 1/Phase 2
Testing ACDN-01 for ABCA4 Stargardt eye disease
This trial tests an experimental medicine called ACDN-01 for people with Stargardt retinopathy caused by ABCA4 gene mutations. The goal is to see if it can slow or stop vision loss in an eye with already damaged central vision.
San Francisco, CaliforniaAges 12 years+ - NCT06471842Recruiting
Eating issues in kids with metabolic diseases on special diets
This trial studies eating disorders in young children with certain inherited metabolic diseases that require a special diet. It aims to understand how often these eating problems happen and what they look like.
ParisAges 1–6 - NCT06445322Recruiting
Finding people with Stargardt disease for ACDN-01
This prescreening study looks for people with a specific genetic eye condition called Stargardt disease to see if they might be able to join a future trial for a new treatment called ACDN-01.
San Francisco, CaliforniaAges 5 years+ - NCT06451757RecruitingPhase 3
Sonlicromanol for chronic fatigue in primary mitochondrial disease
This trial tests a new medicine, sonlicromanol, to see if it can ease chronic fatigue and improve muscle function in people with a specific genetic condition called primary mitochondrial disease. If effective, it could offer a new treatment option to improve daily energy and quality of life.
Boston, MassachusettsAges 18 years+ - NCT06448637Recruiting
Drug balloon vs. medicated stent for large heart arteries
This study compares two treatments for new blockages in large heart arteries: a drug-coated balloon (a balloon that releases medicine) versus a drug-coated stent (a small mesh tube). The goal is to see which one better helps the artery stay open and function normally.
BarcelonaAges 18 years+ - NCT06455280RecruitingPhase 1
A study of Siplizumab for autoimmune liver disease patients awaiting transplant
This trial tests a drug called Siplizumab in people with autoimmune hepatitis or primary sclerosing cholangitis who are on the liver transplant waitlist. It aims to see if the drug can help manage their condition before and after transplant.
New York, New YorkAges 18 years+ - NCT06455384Recruiting
Studying a digital tool for genetic testing services
This trial tests a new online tool called the Genetics Navigator, which helps people access genetic testing services more easily. If you or your child have been referred for genetic testing at Mount Sinai Hospital or SickKids in Toronto, this study may help you manage the process online.
Toronto, OntarioAges 18 years+ - NCT06431633RecruitingPhase 3
Sacituzumab and zimberelimab for lung cancer after surgery
This trial tests a combination of two drugs (sacituzumab and zimberelimab) for people with non-small cell lung cancer that was confined to the chest, was surgically removed, but not completely cleared by prior chemotherapy and immunotherapy. The goal is to see if this treatment can help prevent the cancer from coming back.
Alicante, AlicanteAges 18 years+ - NCT06432582Recruiting
Liver disease blood marker study for people with stiff livers
This study looks at whether certain micro-RNA levels in your blood can help predict how your chronic liver disease is progressing. It is for people who already have some liver stiffness (measured by a special ultrasound) and are being treated at the University Hospital St. Pölten.
Sankt Pölten, Lower AustriaAges 18 years+ - NCT06439862Recruiting
Quality of life in children with posterior urethral valves
This study looks at how children with posterior urethral valves (a condition that affects urination) feel about their quality of life as they grow up. It will help doctors understand how these children are doing emotionally and socially, so they can improve care.
Bron, BronAges 6–17 - NCT06439082RecruitingPhase 3
Crizanlizumab for sickle cell pain crises
This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.
Birmingham, AlabamaAges 12–100 - NCT06430801RecruitingPhase 3
Study of tulisokibart for moderate to severe Crohn's disease
This trial tests a new medicine called tulisokibart for people with moderate to severe Crohn's disease. The medicine may help reduce inflammation and improve symptoms. It is for those who have not had success with other treatments.
Dothan, AlabamaAges 16–80
Hear when a new No Disease or Condition is Being Studied trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for no disease or condition is being studied?
- Yes. Clin2 currently lists 18,404 recruiting no disease or condition is being studied studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a no disease or condition is being studied trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a no disease or condition is being studied trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.